Eisai Pharma is set to establish a Global Capability Center in Visakhapatnam, aiming to boost digital transformation in India ...

Eisai Pharma, a noted human health care pharmaceutical company with a global presence, announced its plans to establish a new ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.

Visakhapatnam: Eisai Pharma, a noted human health care pharmaceutical company, announced its plans to establish a new global ...

Eisai officials said the new study recruited 1,795 people with earlier Alzheimer's disease and amyloid beta in the brain. Participants received either a 10 mg per kilogram dose every two weeks ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

Eisai Europe’s headquarters were expanded to become Eisai Europe, Middle East, Africa and Russia in March 2012. Gary joined Eisai in 2008 as European Commercial Development Director.

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Review the current Eisai Co Ltd (4523:XTKS) dividend yield and history to decide if 4523 is the best investment for you. 4523 - Eisai Co Ltd Dividends | Morningstar Morningstar brands and products ...

Eisai Co., Ltd. and Biogen Inc. announced that the European Commission has granted marketing authorization for lecanemab, marketed as Leqembi®, making it the first therapy in the EU to target an ...

Eisai employs 1,680 people in the U.S. and more than 10,000 people around the world. At its Nutley headquarters, the company has almost 700 employees.